HMS-DCE Website
Course Info

Breast Cancer:
Current Controversies | New Horizons

July 15-17, 2010 •  Renaissance Boston Waterfront Hotel, Boston, MA

Offering up to 20.75 AMA PRA Category 1 Credit(s)™

Offered by:
Dana Farber / Brigham and Women’s Cancer Center
Massachusetts General Hospital Cancer Center

Course Directors:
Judy E. Garber, MD, MPH, Barbara L. Smith, MD, PhD, and Eric P. Winer, MD

Greetings!

We invite you to attend the 2010 Breast Cancer | New Horizons | Current Controversies, a three-day course jointly sponsored by Harvard Medical School, Dana-Farber/Brigham and Women’s Cancer Center, and Massachusetts General Hospital Cancer Center.

This is our 9th year leading this international course, which annually attracts 350-400 oncology clinicians. During that time, the quality of our faculty has been consistently rated above average in terms of educational content, presentation, and relevance to practice. Last year, 99% of our learners told us the course provided the most up-to-date information that could be immediately translated into their practices, while 92% rated the course above average or superior to other post-graduate courses.

We understand that time constraints and economic considerations mean you're being more selective than ever when planning your continuing education. That’s why we recently conducted a needs-assessment study with many of you. Based on your input, everything about this course, from the curriculum to the accommodations, has been designed to give you the greatest possible value.

This year’s curriculum will address seven key learning objectives:

  1. Review breast cancer risk factors and the controversies related to screening
  2. Examine pre-operative therapy challenges
  3. Understand the evolving approaches to pre-invasive disease
  4. Examine the latest protocols for determining who benefits from adjuvant and neoadjuvant therapies; anticipate, identify, and manage side e"ects in order to improve patients’ quality of life and compliance
  5. Explore the current surgical options for patients with breast cancer or increased risk
  6. Discuss the molecular heterogeneity of breast cancer and its therapeutic implications
  7. Review and discuss emerging clinical trial results on multiple aspects of breast cancer diagnosis, management, and treatment selected by experts as having practical application to current clinical practice

The course will also feature more opportunities for specialized learning and personal interactions between faculty and learners:

  • Concurrent small group work sessions and discussion groups that address specific clinical challenges.
  • Challenging, multidisciplinary case studies and tumor panels to facilitate the exchange of best practices.
  • A presentation of highlights from ASCO, followed by a discussion of the practice implications.
  • 59 world-renown faculty

Because we believe our learners benefit from a "campus-like" experience, we have negotiated a special rate with our hotel partner, the brand new Renaissance Boston Waterfront Hotel—$185 per night, $100 less than last year. We’ve also added a cocktail reception with faculty on Thursday evening and will be providing lunch on Friday.

We hope you'll join us this July. We think you'll find our course to be a unique and valuable learning experience.

Please register early as seats!are limited and the course fills up quickly.

Best,

Judy E. Garber, MD, MPH
Director, Friends Cancer Risk and Prevention Clinic,
Dana-Farber Cancer Institute

Barbara L. Smith, MD, PhD
Director, Gillette Center for Breast Cancer,
Massachusetts General Hospital Cancer Center

Eric P. Winer, MD
Thompson Senior Investigator and Chief,
Division of Women’s Cancers, Dana-Farber Cancer Institute

NEEDS ASSESSMENT SURVEY

The design of this year’s course and the development of our learning objective were derived from the results of a needs assessment study with our target learners. The study highlights both knowledge and practice gaps of our specific target learners, to review the results of the self-assessment study just visit: http://cme.med.harvard.edu/cmeups/pdf/00301279_NeedsAssessmentSurvey.pdf.

Last update 03.08.10

OBJECTIVE

  • Review breast cancer risk factors and the controversies related to screening
  • Examine pre-operative therapy challenges
  • Understand the evolving approaches to pre-invasive disease
  • Examine the latest protocols for determining who benefits from adjuvant and neoadjuvant therapies; anticipate, identify, and manage side e"ects in order to improve patients’ quality of life and compliance
  • Explore the current surgical options for patients with breast cancer or increased risk
  • Discuss the molecular heterogeneity of breast cancer and its therapeutic implications
  • Review and discuss emerging clinical trial results on multiple aspects of breast cancer diagnosis, management, and treatment selected by experts as having practical application to current clinical practice.

ADVANCES. CHALLENGES.

Revolutionary advances in cell biology, genetics, neoadjuvant treatment strategies, and surgical techniques are o"ering new options for diagnosing, treating, and overcoming breast cancer. Jointly sponsored by Harvard Medical School, Dana-Farber/Brigham and Women’s Cancer Center, and Massachusetts General Hospital Cancer Center, this three-day course provides the most up-to-date, in-depth focus on this disease—from its pathogenesis to the economics of breast care health.

WORLD-CLASS FACULTY. MULTIDISCIPLINARY APPROACH.

The course offers a rare gathering of world-class educators in medical, surgical, and radiation oncology who will discuss challenging clinical cases, address controversial topics, and offer practical treatment strategies. Using a multidisciplinary approach, the course will enable you to:

  • Become acquainted with the latest disease research, medications, therapies, and clinical trials, and the implications for your practice.
  • Have the opportunity for one-to-one conversations about your clinical challenges.
  • Learn about the key findings from the 2010 ASCO conference.
  • Engage faculty in a range of settings, including small group courses, panel discussions, challenging case discussions, one-to-one conversations, and networking.

TARGET LEARNERS

Medical oncologists, surgical oncologists, radiation oncologists, breast surgeons, internists, physician’s assistants, nurse practitioners, oncology nurses, breast cancer advocates and others interested in the care of women with breast cancer.

COMMERCIAL SUPPORT

The conference organizers are applying for unrestricted educational grants in support of this program. The list of contributors will be provided at the conference. All Harvard Medical School programs are organized solely to promote the exchange and dissemination of scientific and medical information. No promotional content is permitted.

There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Harvard Medical School.

No cameras, tape recorders, or other recording devices are permitted in the meeting room.

Name badges will be provided onsite and, for security reasons, are required for admission to all sessions.

NEW THIS YEAR

  • Concurrent small group work sessions and discussions on clinical challenges
  • 2010 ASCO highlights
  • Eight panel discussions with Q&As
  • Two workshops on challenging multidisciplinary cases
  • Cocktail reception with faculty Thursday evening and work session with complimentary lunch on Friday
  • Brand new hotel venue with special $185 room rate - $100 savings over last year
  • Earn up to 20.75 AMA PRA Category 1 Credit(s)™

Attendance Limited

No time to register now? Add your name to the mailing list to receive future notices about this course!
BREAST CANCER: CURRENT CONTROVERSIES AND NEW HORIZONS
Renaissance Boston Waterfront Hotel

THURSDAY, JULY 15, 2010
7:15 Registration and Continental Breakfast
8:00 Welcoming Remarks
Eric P. Winer, MD, Dana-Farber/Brigham and Women’s Cancer Center
8:10 Jean H. Lubrano Distinguished Visiting Scholar Lecture
The Role of PARP Inhibition in Breast Cancer Treatment
Andrew Tutt, MRCP, FRCR, PhD, Kings College London School of Medicine
SESSION I –  RISK AND SCREENING
Moderator: Judy E. Garber, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center
8:50 Modifiable Breast Risk Factors: Alcohol, Diet, and Exercise
Wendy Y. Chen, MD, Dana-Farber/Brigham and Women’s Cancer Center
9:10 BRCA1, 2 and Beyond
Susan M. Domcheck, MD, University of Pennsylvania Rena Rowan Breast Center
9:30 The Mammographic Screening Controversy
Ellen Warner, MD, FRCPC, FACP, M.Sc., Sunnybrook Research Institute, Toronto, ON
10:00 Panel Discussion with Q&A
10:20 Break
SESSION II –  PRE-INVASIVE DISEASE
Moderator: Kevin S. Hughes, MD, Massachusetts General Hospital Cancer Center
10:40 Are We Over-Diagnosing Pre-Invasive Disease?
Laura Esserman, MD, MBA, Univeristy of California, San Francisco
11:00 The Pathology of DCIS and Other Pre-Invasive Lesions
Laura C. Collins, MD, Beth Israel Deaconess Medical Center
11:20 Modern Surgical Approaches to DCIS
Mehra Golshan, MD, FACS, Dana-Farber/Brigham and Women’s Cancer Center
11:40 Do All Patients with DCIS Need Radiation After Conservative Surgery?
Julia Wong, MD, Dana-Farber/Brigham and Women’s Cancer Center
12:00 Panel Discussion with Q&A
12:20 Break (Lunch on your own)
1:30 Challenging Cases –  Early Stage Disease
Moderator: Craig A. Bunnell, MD, MBA
Dana-Farber/Brigham and Women’s Cancer Center
Panelists:
Elizabeth Rafferty, MD, Massachusetts General Hospital
Jane Brock, MD, Brigham and Women’s Hospital
Michele A. Gadd, MD, Massachusetts General Hospital Cancer Center
Rinaa Punglia, MD, Dana-Farber/Brigham and Women’s Cancer Center
Eric P. Winer, MD, Dana-Farber/Brigham and Women’s Cancer Center
Steven J. Isako3, MD, PhD, Massachusetts General Hospital Cancer Center
SESSION III –  CHALLENGES IN PREOPERATIVE THERAPY
Moderator: J. Dirk Iglehart, MD, Dana-Farber/Brigham and Women’s Cancer Center
2:30 Identifying Candidates for Preoperative Therapy
J. Dirk Inglehart, MD, Dana-Farber/Brigham and Women’s Cancer Center
2:50 Preoperative Therapy for Triple Negative Disease
Judy E. Garber, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center
3:10 Preoperative Therapy for HER2+ Disease
Lyndsay Harris, MD, Yale University School of Medicine
3:30 Preoperative Therapy for ER+ Disease
Matthew Ellis, MD, Washington University
3:50 Panel Discussion with Q&A
4:10 Break
4:30 Imaging the Patient Receiving Preoperative Therapy
Eren Yeh, MD, Dana-Farber/Brigham and Women’s Cancer Center
4:50 Pathology Assessment After Preoperative Therapy
Andrea Richardson, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center
5:10 Surgery Issues After Preoperative Therapy
Funda Meric-Berstram, MD, MD Anderson Cancer Center
5:30 Radiation Therapy Challenges After Preoperative Therapy
Jennifer Bellon, MD, Dana-Farber/Brigham and Women’s Cancer Center
5:50 Panel Discussion with Q&A
6:10 Closing Remarks
6:15 Complimentary wine and cheese reception with faculty
FRIDAY, JULY 16, 2010
6:30 Continental Breakfast
7:30 Concurrent Small Group Work Sessions And Discussions On Clinical Challenges
Please indicate your top three choices in order of preference when registering for the course.
A. Enhancing Supportive Care for Our Patients
Jennifer Belmonte, Surgical PA, Massachusetts General Hospital Cancer Center
Georgia Litsas, NP, Dana-Farber/Brigham and Women’s Cancer Center
Note: This concurrent session is designed specifically for NPs, PAs, and RNs
B. Managing the Extra-Axillary Sentinel Node and Positive Internal Mammary Nodes
Funda Meric-Berstram, MD, MD Anderson Cancer Center
C. Role of Surgery in Stage IV Disease
Susan Troyan, MD, Dana-Farber/Brigham and Women’s Cancer Center
Sara Tolaney, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center
D. Partial Breast Irradiation
Shannon MacDonald, MD, Massachusetts General Hospital Cancer Center
E. Bisphosphonates in the Adjuvant Setting
Julie Gralow, MD, Seattle Cancer Care Alliance
F. Special Considerations for Managing Breast Cancer in Young Women
Ann Partridge, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center and
Lidia Schapira, MD, Massachusetts General Hospital Cancer Center
G. New Targets for Triple Negative Breast Cancer
Daniel P. Silver, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center
H. Adjuvant Treatment in the Elderly
Mike Hassett, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center
Rachel Freedman, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center
I. Managing Menopausal Symptoms Jennifer A. Ligibel, MD, Dana-Farber/Brigham and Women’s Cancer Center
J. Incorporating Genetics into Oncology Practice Susan M. Domcheck, MD, University of Pennsylvania Rena Rowan Breast Center
K. CYP2D6 Testing
Kathryn Ruddy, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center
Harold J. Burstein, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center
L. Immunotherapy for Breast Cancer
Karen S. Anderson, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center
8:30 Judith P. Schlager Lecture
Advances in Radiation Oncology
Alain Fourquet, MD, Institut Curie, Paris, France
9:30 Break
SESSION IV –  ADVANCED BREAST CANCER
Moderator: Eric P. Winer, MD, Dana-Farber/Brigham and Women’s Cancer Center
9:50 What Outcomes Matter in Clinical Trials in Metastatic Disease
Nancy U. Lin, MD, Dana-Farber/Brigham and Women’s Cancer Center
10:10 HER2+ Breast Cancer: The Present and Future
Ian E. Krop, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center
10:30 How Can We Improve Endocrine Therapy for Advanced Breast Cancer
C. Kent Osborne, MD, Baylor Cancer Center
10:50 Angiogenesis Inhibitors: A Major Advance?
Erica Mayer, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center
11:10 Tumor Heterogeneity: The Real Challenge
Kornelia Polyak, MD, PhD, Dana-Farber Cancer Institute
11:45 Panel Discussion with Q&A
12:15 Break
12:30 Lunch Served
Challenging Multidisciplinary Cases –  Early Stage and Advanced Disease
Moderator: Harold J. Burstein, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center
Panelists: Melinda Lerwill, MD, Massachusetts General Hospital Cancer Center
Jennifer McKenna, NP, Dana-Farber/Brigham and Women’s Cancer Center
Jay Harris, MD, Dana-Farber/Brigham and Women’s Cancer Center
Monica Morrow, MD, FACS, Memorial Sloan-Kettering Cancer Center
Paula Ryan, MD, Massachusetts General Hospital Cancer Center
Jerry Younger, MD, Massachusetts General Hospital Cancer Center
1:45 21 Break
SESSION V –  ADVANCES AND CONTROVERSIES IN LOCAL THERAPY
Moderator: Michelle C. Specht, MD, Massachusetts General Hospital Cancer Center
2:00 21 Innovation in Lumpectomy and Mastectomy Surgery
Barbara L. Smith, MD, PhD, Massachusetts General Hospital Cancer Center
2:20 21 Surgical Management of the Patient with a Positive Sentinel Node
Susan Troyan, MD, Dana-Farber/Brigham and Women’s Cancer Center
2:40 21 Post-Mastectomy Radiation for Fewer than Four Nodes
Jay R. Harris, MD, Dana-Farber/Brigham and Women’s Cancer Center
3:00 21 Breast Reconstruction: Which Option for Which Patient?
Stephanie Caterson, MD, Brigham and Women’s Hospital
3:20 21 Can We Reverse the Trend Toward Bilateral Mastectomies?
Monica Morrow, MD, FACS, Memorial Sloan-Kettering Cancer Center
3:40 21 Panel Discussion with Q&A
4:00 21 Break
4:20 21 New England Journal Of Medicine Clinicopathological Conference
Patient with Inflammatory Breast Cancer
Moderator: Nancy Lee Harris, MD, Massachusetts General Hospital
Discussant: Beth Overmoyer, MD, Dana-Farber/Brigham and Women’s Cancer Center
5:20 21 Closing Remarks and Adjourn –  Day 2
SATURDAY, JULY 17, 2010
7:15 Continental Breakfast
8:00 Susan E. Donelan "hope For The Future" Lecture
A Balancing Act: Comparative Effectiveness vs. Efficacy and the Cancer Research Agenda
Deborah Schrag, MD, Dana-Farber/Brigham and Women’s Cancer Center
SESSION VI –  CONTROVERSIES AND UPDATE
8:45 ASCO Update
Harold J. Burstein, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center
SESSION VII –  ADJUVANT THERAPY
Moderator: Barbara L. Smith, MD, PhD, Massachusetts General Hospital Cancer Center
9:15 Which Patients Don't Need Chemotherapy?
Julie Gralow, MD, Seattle Cancer Care Alliance
9:35 Picking the Optimal Adjuvant Endocrine Therapy for Post-Menopausal Women
William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center
9:55 Picking the Optimal Adjuvant Endocrine Therapy for Pre-Menopausal Women
Ann Partridge, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center
10:15 Break
10:30 Frontiers in the Adjuvant Treatment of HER2+ Disease
Eric P. Winer, MD, Dana-Farber/Brigham and Women’s Cancer Center
10:50 Picking the Optimal Adjuvant Chemotherapy Regimen
Giuseppe Curigliano, MD, European Institute of Oncology, Milan, Italy
11:10 Minimizing Toxicity of Adjuvant Therapy: Symptom Management
Charles Loprinzi, MD, Mayo Clinic
11:30 Panel Discussion with Q&A
12:15 Concluding Remarks and Adjourn
Eric P. Winer, MD, Dana-Farber/Brigham and Women’s Cancer Center

ACCREDITATION

Physician: Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Harvard Medical School designates this educational activity for a maximum of 20.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse: Nursing continuing education hours (20.75) have been requested. Dana-Farber Cancer Institute is an approved provider of continuing nursing education by the Massachusetts Association of Registered Nurses, Inc., an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

REGISTRATION INFORMATION

Register Online   (By CC)
Register by Mail    (PDF)

Full Tuition (Registrations postmarked after May 1, 2010)
Physicians: $600 (USD)
Nurse Practitioners, Nurses, and Allied Health Professionals: $500 (USD)
Residents/Fellows in Training: $425 (USD)

* A letter of verification from Department Chairman must accompany registration form/payment for a reduced fee for Residents/ Fellows in Training.

All foreign payments must be made by a draft on a United States Bank or by Visa or MasterCard.

If paying by CHECK, please make payable to Harvard Medical School and mail with completed registration form to Harvard Medical School‑Department of Continuing Education, PO Box 825, Boston, MA 02117‑0825.

If paying by credit card, please register online here.

Telephone or mail‑in registration with credit card payment is not accepted.

Inquiries should be directed to the above address, made by phone: (617) 384‑8600, Monday ‑ Friday, 10 AM to 4 PM (EST), or by email: hms‑cme@hms.harvard.edu

Upon receipt of your registration form an email confirmation from the HMS-DCE office will be sent to you. Therefore, be sure to include an email address that you check daily/frequently. Your email address is used for critical information about the course including: registration confirmation, course evaluation and certificate.

TUITION REFUND POLICY

A handling fee of $60 is deducted for cancellation. Refund requests must be received by mail one week prior to the course. No refunds will be made thereafter.

COURSE LOCATION

Renaissance Boston Waterfront Hotel
Renaissance Boston Waterfront
606 Congress Street, Boston, MA 02210
617-338-4111
www.renaissanceboston.com

ACCOMMODATIONS

The new Renaissance Boston Waterfront Hotel is offering a special room rate of $185 per night.

With its convenient downtown Boston location, spectacular waterfront views, and luxurious amenities and services, the newly opened Renaissance Boston Waterfront Hotel provides an exceptional setting for our course. A limited block of rooms has been reserved for a special rate of $185/night (deluxe room, USD plus applicable tax, currently 14.45%).

Call 617-338-4111 or visit: https://resweb.passkey.com/go/knowledgetopractice for online reservations. Please identify yourself as a "Breast Cancer Course" attendee to receive the reduced room rate. Rooms are limited, so please book early.

TRAVEL

Please do not make non-refundable airline reservations until you have been confirmed into your course. You can make your airline reservation by calling the HMS Travel Desk toll free 1(877) 4-HARVMD (1-877-442-7863) Monday - Friday 9 AM - 8 PM (EST). From outside the U.S., Canada and Virgin Islands, please call (617) 559-3764.


[Faculty]
Harvard Faculty
Karen S. Anderson, MD, PhD
Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Jennifer Bellon, MD
Assistant Professor of Radiation Oncology, Harvard Medical School; Radiation Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Jennifer Belmonte, PA
Surgical PA, MGH Cancer Center
Jane E. Brock, MD, BcH, PhD
Instructor in Pathology, Harvard Medical School; Pathologist, Dana-Farber/Brigham and Women’s Cancer Center
Craig A. Bunnell, MD, MPH, MBA
Associate Chief Medical Officer, Dana-Farber Cancer Institute; Assistant Professor of Medicine; Harvard Medical School
Harold J. Burstein, MD, PhD
Associate Professor of Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Stephanie Caterson, MD
Instructor in Surgery, Harvard Medical School; Surgeon, Brigham and Women’s Hospital
Wendy Y. Chen, MD
Assistant Professor of Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Laura Collins, MD
Assistant Professor of Pathology, Harvard Medical School; Associate Director, Division of Anatomic Pathology, Beth Israel Deaconess Medical Center
Rachel Freedman, MD, MPH
Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Michelle Gadd, MD
Assistant Professor of Surgery, Harvard Medical School; Surgical Oncologist, Massachusetts General Hospital Cancer Center
Judy E. Garber, MD, MPH
Associate Professor of Medicine, Harvard Medical School; Director, Friends Cancer Risk and Prevention Clinic, Dana-Farber/Brigham and Women’s Cancer Center
Mehra Golshan, MD, FACS
Assistant Professor of Surgery, Harvard Medical School; Director of Breast Surgical Services, Dana-Farber/Brigham and Women’s Cancer Center
Jay R. Harris, MD
Professor and Chair, Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School
Nancy Lee Harris, MD
Austin L. Vickey Professor of Pathology, Harvard Medical School; Pathologist, Director of Hematopathology, Massachusetts General Hospital; Editor, Case Records of the Massachusetts General Hospital, New England Journal of Medicine
Michael J. Hassett, MD, MPH
Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Kevin S. Hughes, MD
Associate Professor of Surgery, Harvard Medical School; Surgical Oncologist, Massachusetts General Hospital Cancer Center
J Dirk Iglehart, MD
Anne E. Dyson Professor of Women’s Cancers, Harvard Medical School; Director, Women’s Cancers Program, Dana-Farber Cancer Institute
Steve Isakoff, MD, PhD
Instructor in Medicine, Harvard Medical School; Medical Oncologist, Massachusetts General Hospital Cancer Center
Ian E. Krop, MD, PhD
Assistant Professor of Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Melinda J. Lerwill, MD
Assistant Professor of Pathology, Harvard Medical School; Staff Pathologist, Massachusetts General Hospital
Jennifer A. Ligibel, MD
Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Nancy U. Lin, MD
Assistant Professor of Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Georgia Litsas, MSN, RN, NP
Nurse Practitioner, Gillette Center for Women’s Cancers, Dana-Farber/Brigham and Women’s Cancer Center
Shannon M. MacDonald, MD
Assistant Professor of Radiation Oncology, Harvard Medical School; Radiation Oncologist, Massachusetts General Hospital Cancer Center
Erica L. Mayer, MD, MPH
Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Jennifer McKenna, RN, MSN, AOCNP
Nurse Practitioner, Gillette Center for Women’s Cancers, Dana-Farber/Brigham and Women’s Cancer Center
Beth Overmoyer, MD, FACP
Assistant Professor of Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Kornelia Polyak, MD, PhD
Associate Professor of Medicine; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Ann H. Partridge, MD, MPH
Assistant Professor of Medicine, Harvard Medical School; Clinical Director, Breast Oncology Center, Dana-Farber/Brigham and Women’s Cancer Center; Director, Program for Young Women with Breast Cancer, Dana-Farber Cancer Institute
Rinaa Punglia, MD, MPH
Assistant Professor of Radiation Oncology, Harvard Medical School; Radiation Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Elizabeth Rafferty, MD
Professor of Radiology, Harvard Medical School
Andrea Richardson, MD, PhD
Assistant Professor of Pathology, Harvard Medical School; Staff Pathologist, Brigham and Women’s Hospital
Kathryn Ruddy, MD, MPH
Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Paula D. Ryan, MD, PhD
Assistant Professor of Medicine, Harvard Medical School; Medical Director, Breast and Ovarian Cancer Genetics and Risk Assessment Program, Massachusetts General Hospital Gillettee Center for Breast Cancer
Lidia Schapira, MD
Associate Professor of Medicine, Harvard Medical School; Medical Oncologist, Massachusetts General Hospital Cancer Center
Deborah Schrag, MD
Associate Professor of Medicine, Harvard Medical School; Medical Oncologist, Center for Outcome Policy and Research, Dana-Farber/Brigham and Women’s Cancer Center
Daniel P. Silver, MD, PhD
Assistant Professor of Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Barbara Smith, MD, PhD
Associate Professor of Surgery Harvard Medical School; Director, Gillette Center for Breast Cancer, Massachusetts General Hospital Cancer Center
Michelle C. Specht, MD
Instructor in Surgery, Harvard Medical School; Assistant in Surgery, Massachusetts General Hospital Cancer Center
Sara M. Tolaney, MD, MPH
Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Susan Troyan, MD
Instructor in Surgery, Harvard Medical School; Surgical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Eric P. Winer, MD
Professor of Medicine, Harvard Medical School; Thompson Senior Investigator and Chief, Division of Women’s Cancers, Dana-Farber Cancer Institute
Julia Wong, MD
Assistant Professor of Radiation Oncology, Harvard Medical School; Radiation Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
Erin Yeh, MD
Assistant Professor of Radiology, Harvard Medical School; Radiologist, Dana-Farber/Brigham and Women’s Cancer Center
Jerry Younger, MD
Assistant Professor of Medicine, Harvard Medical School; Medical Oncologist, Massachusetts General Hospital Cancer Center
Guest Faculty
Giuseppe Curigliano, MD, PhD
Senior Deputy Director, Division of Medical Oncology, European Institute of Oncology IEO, Milan, Italy
Susan Domchek, MD
Associate Professor of Medicine; Director of the MacDonald Cancer Risk Evaluation Program, Senior Fellow, Leonard David Institute of Health Economics, University of Pennsylvania, Abramson Cancer Center
Matthew Ellis, MD
Professor, Department of Medicine, Washington University; Director, Breast Health Program, Washington University and Barnes-Jewish Hospital; Co-Director, Clinical and Translational Research, Siteman Comprehensive Cancer Center
Laura J. Esserman, MD, MBA
Professor, Surgery and Radiology, and Affiliate Faculty, Institute for Health Policy Studies, University of California at San Francisco; Director, Carol Franc Buck Breast Care Center; Co-Leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
Alain Fourquet, MD, Institut Curie William J. Gradishar, MD
Professor of Medicine, Northwestern University Feinberg School of Medicine; Director, Breast Medical Oncology, Program Director, Hematology/Oncology Fellowship Program, Robert H. Lurie Comprehensive Cancer Center
Julie Gralow, MD
Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine; Director of Breast Medical Oncology at Seattle Cancer Care Alliance.
Lyndsay N. Harris, MD
Associate Professor Yale University School of Medicine; Co-Director, Breast Cancer Program, Yale-New Haven Hospital
Charles L. Loprinzi, MD
Regis Professor of Breast Cancer Research, Mayo Clinic; Rochester, MN
Funda Meric-Bernstam, MD
Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center
Monica Morrow, MD, FACS
Chief, Breast Surgical Service, Anne Burnett Windfohr Chair of Clinical Oncology, Professor of Surgery, Weill Medical College of Cornell University
C. Kent Osbourne, MD
Director, Dan L. Duncan Cancer Center, Director, Lester and Sue Smith Breast Center, Professor of Medicine and Molecular and Cellular Biology, Dudley and Tina Sharp Chair for Cancer Research, Baylor College of Medicine
Andrew Tutt, MB, ChB, PhD, MRCP, FRCR
Consultant Clinical Oncologist/Director, Breakthrough Breast Cancer Research Unit, Research Oncology, Kings Health Partners, London, UK
Ellen Warner, MD, FRCPC, FACP, MSc
Associate Scientist, Sunnybrooke Health Sciences Centre, Toronto

Last update 04.13.10